Key result
Prophylactic administration of atenolol, propranolol, oxprenolol, or disopyramide phosphate did not significantly reduce mortality in patients with suspected acute myocardial infarction.
Why the study?
Does prophylactic treatment with atenolol, propranolol, oxprenolol, or disopyramide phosphate reduce mortality in patients with suspected acute myocardial infarction?
RCT (n=861)
Randomly allocated
Does prophylactic treatment with atenolol, propranolol, oxprenolol, or disopyramide phosphate reduce mortality in patients with suspected acute myocardial infarction?
Answers are grounded in this paper and cite their sources.
Prophylactic administration of beta-blockers or disopyramide phosphate in suspected acute myocardial infarction does not reduce mortality, and disopyramide may increase the risk of heart failure.
The value of beta-blockade and of disopyramide phosphate in the immediate treatment of patients with suspected acute myocardial infarction was assessed in two placebo controlled trials. In the first study 388 patients with suspected acute myocardial infarction were randomly allocated to treatment with propranolol, atenolol, or placebo, and when analysed on an initial intention to treat basis there was no significant difference between the three groups in respect of the mortality at one year. In addition, there was no evidence to suggest that either atenolol, or propranolol reduced the incidence of 'serious' ventricular arrhythmias in the coronary care unit. In the second study 473 patients with suspected acute myocardial infarction were randomly allocated to treatment with oxprenolol, disopyramide phosphate, or placebo. Again no significant differences were seen with respect to the mortality at six weeks. There was, however, a significantly increased incidence of heart failure in the group which received disopyramide phosphate. Patients who received this drug also showed a reduced number of dysrhythmic episodes on 24-hour ECG recordings, but this trend did not achieve statistical significance. These results suggest that none of the three beta-blockers tested nor disopyramide phosphate is likely to reduce the mortality from acute myocardial infarction when given prophylactically, although disopyramide phosphate does reduce the incidence of 'serious' ventriicular arrhythmias.
No takes yet. Share an insight, caveat, or question.
Rosalinde G. Wilcox (1981) conducted an RCT in Suspected acute myocardial infarction (n=861). Atenolol, propranolol, oxprenolol, or disopyramide phosphate vs. Placebo was evaluated on Mortality at one year (Study 1) and six weeks (Study 2). Prophylactic administration of atenolol, propranolol, oxprenolol, or disopyramide phosphate did not significantly reduce mortality in patients with suspected acute myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: